Welcome to our dedicated page for Inovio Pharmaceu news (Ticker: INO), a resource for investors and traders seeking the latest updates and insights on Inovio Pharmaceu stock.
Inovio Pharmaceuticals reports developments in DNA medicines for HPV-related diseases, cancer and infectious diseases. Its updates center on INO-3107, a DNA immunotherapy candidate for recurrent respiratory papillomatosis, including clinical data, scientific publications, FDA review milestones and presentations at medical and biotechnology conferences.
Company news also includes quarterly and annual financial results, business updates, research on DNA-encoded monoclonal antibodies and DNA-encoded protein technology, collaboration activity and capital-structure actions involving common stock, warrants and at-the-market financing programs.
INOVIO (NASDAQ: INO) and Akeso announced a clinical collaboration to evaluate INO-5412 plus Akeso's cadonilimab in glioblastoma as part of the Phase 2 INSIGhT adaptive platform trial.
Dosing is expected to begin in H2 2026. The program builds on prior positive Phase 2 immune responses with INO-5401 and leverages cadonilimab's China approvals and ongoing Phase 3/registration studies.
INOVIO (NASDAQ:INO) announced participation in multiple scientific and investor conferences between Feb 18 and Mar 10, 2026. Management will present posters and talks on INO-3107, SARS-CoV-2 DMAbs phase 1 data, and hold investor fireside chats and one-on-one meetings.
Webcasts and replay links are provided for investor events; abstracts will be posted on the company website after each presentation.
INOVIO (NASDAQ: INO) announced the U.S. FDA accepted its Biologics License Application (BLA) for INO-3107 to treat adults with recurrent respiratory papillomatosis (RRP).
FDA assigned a PDUFA goal date of October 30, 2026 and classified the review as Standard. The FDA indicated it is not currently planning an advisory committee meeting.
The BLA was filed under the accelerated approval pathway; FDA flagged a potential review issue, preliminarily finding inadequate information to justify accelerated approval. INOVIO plans to request a meeting with FDA and continues to believe INO-3107 meets accelerated approval criteria. The BLA includes Phase 1/2 data and long-term durability results published in Nature Communications and The Laryngoscope.
INOVIO (NASDAQ: INO) announced an equity inducement grant under its 2022 Inducement Plan for a newly hired employee. The Compensation Committee approved an option to purchase 24,000 shares with a Grant Date of November 28, 2025.
The option has an exercise price of $2.06 (INOVIO closing price on the Grant Date) and vests over three years with one-third vesting on each of the first, second and third anniversaries of the Grant Date, subject to continued employment and the terms of the stock option agreement. The award was granted in accordance with Nasdaq Listing Rule 5635(c)(4).
INOVIO (NASDAQ:INO) will participate in two investor conferences in New York in December 2025. Management will appear at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2 for an 8:30–8:55 AM ET fireside chat (live webcast and 90‑day replay available) and at the Oppenheimer Movers in Rare Disease Summit on Thursday, December 11 for a 12:05–12:25 PM ET panel featuring elevator pitches of near‑term catalysts. Members of INOVIO management will also hold one‑on‑one investor meetings during both events.
Webcast link for the Piper Sandler presentation: https://bit.ly/44af19l.
INOVIO (Nasdaq: INO) priced an underwritten public offering of 13,158,000 shares of common stock at $1.90 per share, with expected gross proceeds of approximately $25 million.
The company is selling all offered shares and granted the underwriters a 30-day option to purchase up to 1,973,700 additional shares at the public offering price less discounts and commissions. The offering is expected to close on or about November 12, 2025, subject to customary conditions, with Piper Sandler & Co. acting as sole manager.
A shelf registration was filed on November 9, 2023 and declared effective by the SEC on January 31, 2024. Final prospectus supplement will be available through the underwriter and the SEC EDGAR site.
INOVIO (Nasdaq: INO) announced on November 10, 2025 that it intends to offer and sell shares of its common stock in an underwritten public offering, with all shares to be sold by the company.
INOVIO said it will grant the underwriter a 30-day option to buy up to 15% additional shares on the same terms. The offering is subject to market conditions and there is no assurance of timing, size, or terms. Piper Sandler is acting as sole book-running manager. The shares are covered by a shelf registration filed with the SEC on November 9, 2023 and declared effective on January 31, 2024. The offering will be made only by prospectus and prospectus supplement filed with the SEC.
INOVIO (NASDAQ: INO) completed a rolling BLA submission for INO-3107 under FDA accelerated approval and requested priority review; company expects file acceptance by year-end 2025 with a potential PDUFA in mid-2026 if priority review is granted. Commercial preparations target a potential mid-2026 launch and a confirmatory trial is planned to begin during review at ~20 U.S. sites. Clinical highlights: 81% of patients had fewer surgeries at Year 1 and a 78% mean annual surgery reduction at Year 2 versus pre-treatment. Scientific progress includes a Nature Medicine publication on next-generation DMAb technology. Q3 2025 results: R&D $13.3M, G&A $7.9M, total operating expenses $21.2M, net loss $45.5M ($0.87/share) driven by a $22.5M non-cash warrant fair-value loss. Cash $50.8M vs $94.1M at 12/31/24; runway into Q2 2026 with estimated Q4 burn ~$22M.
INOVIO (NASDAQ: INO) completed the rolling submission of a Biologics License Application (BLA) for INO-3107, a DNA immunotherapy for recurrent respiratory papillomatosis (RRP) in adults, submitted under the FDA's Accelerated Approval program.
The program includes prior Orphan Drug and Breakthrough Therapy designations. The company expects FDA file acceptance by year-end 2025 and, if priority review is granted, a potential PDUFA date in mid-2026. If approved, INO-3107 would be INOVIO's first commercial product and the first DNA medicine available in the United States.
INOVIO (NASDAQ:INO) announced an inducement equity award under its 2022 Inducement Plan with a grant date of October 31, 2025.
The Compensation Committee approved an option to purchase 3,000 shares of common stock at an exercise price of $2.35 (the closing price on October 31, 2025). The option vests in thirds over three years (one-third on each of the first, second and third anniversaries) and is subject to continued employment and the Inducement Plan option agreement terms. The award was made to a newly hired employee in accordance with Nasdaq Listing Rule 5635(c)(4).